Hoth Therapeutics Inc HOTH

Healthcare Biotechnology

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

NDAQ:HOTH - Post by User

Hoth Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by 7Twiggyon Jan 18, 2024 2:11pm

45 Views

Post# 35834199

Makes me wonder

The way I understand the news release, this is the second approval for another group
of patients with more serious conditions than the first. You think there must be something positive
going on behind the scenes for this second approval. Guess we will find ou in time.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project